Glycoengineered therapeutic antibodies

Recombinant Antibodies for Immunotherapy

Volumn , Issue , 2009, Pages 144-154

  Brünker, Peter ^a   Sondermann, Peter ^a   Umaña, Pablo ^a  

^a Glycart Biotechnology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956406001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596773.014     Document Type: Chapter

References (28)

1. Clynes R.A. et al. (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443-446.
2. Cartron G. et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FccRIIIa gene. Blood 99(3), 754-758.
3. Weng W.K. and Levy R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21) 3940-3947.
4. Musolino A. et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11) 1789-1796.
5. Umaña P. et al. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotech. 17, 176-180.
6. Jeffries R. et al. (1998) IgG-Fc mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163, 59-76.
7. Lifely M.R. et al. (1995) Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. J. Glycobiol. 5, 813-822.
8. Schachter H. (1986) Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem. Cell. Biol. 64, 163-181.
9. Umaña P. et al. (1999) Glycosylation engineering of antibodies for improving antibodydependent cellular cytotoxicity. US patent 6602684.
10. Brown, M.E. et al. (1992) Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system. Cytotechnology, 9, 231-236.
11. Ferrara C. et al. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous b 1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II. Biotechnol. Bioeng. 93(5), 851-861.
12. Ferrara C. et al. (2006) The carbohydrate at FccRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG. J. Biol. Chem. 281(8), 5032-5036.
13. Shields R.L. et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular cytotoxicity. J. Biol. Chem. 277(26), 26733-26740.
14. Shinkawa T. et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(3), 3466-3473.
15. Hodoniczky J. et al. (2005) Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21(6), 1644-1652.
16. Yamane-Ohnuki N. et al. (2004) Establishment of Fut8 knockout chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87(5), 614-622.
17. Rutishauser U. et al. (1970) The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7. Biochemistry. 9(16), 3171-3181.
18. Deisenhofer J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 20(9), 2361-2370.
19. Walker M.R. et al. (1989) Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FccRI and/or FccRII receptors. Biochem. J. 259(2), 347-353.
20. Sarmay G. et al. (1992) Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcc receptor. Mol. Immunol. 29(5), 633-639.
21. Galfrè G. and Milstein C. (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 73(Pt B), 3-46.
22. Koene H.R. et al. (1997) FccRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FccRIIIa, independently of the FccRIIIa-48L/R/H phenotype. Blood. 90(3), 1109-1114.
23. Louis E. et al. (2004) Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19(5), 511-519.
24. Wu J. et al. (1997) A novel polymorphism of FccRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100(5), 1059-1070.
25. Okazaki A. et al. (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FccRIIIa. J. Mol. Biol. 336(5), 1239-1249.
26. Sondermann P. et al. (2001) Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309(3), 737-749.
27. Sondermann P. et al. (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment- FccRIII complex. Nature. 406(6793), 267-273.
28. Matsumiya S. et al. (2007) Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368(3), 767-779.